Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Want to see AU:GSS full AI Analyst Report?
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.47
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$15.67M
Enterprise Value-AU$864.42K
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.10Price Target Upside-58.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$18.20M
Bulls Say, Bears Say
Bulls Say
Proprietary 3base Technology And Multiplex Assay MenuOwning a proprietary 3base technology and a broad multiplex assay menu provides product differentiation and technical barriers to entry. This supports durable laboratory adoption, enables bundled panels, and sustains competitive positioning and pricing power across clinical and reference lab customers.
Recurring Consumables Revenue ModelA consumables-led business tied to installed test throughput creates repeatable, usage-linked revenue. As labs run more patient tests, kit reorders recur, giving predictable long-term demand scaling with adoption of assays and supporting gross revenue durability versus one-time instrument sales.
Low Leverage And Strong Equity PositionExtremely low debt and a solid equity base preserve financial flexibility, reduce solvency risk, and lengthen runway to fund R&D or market expansion. This structural balance-sheet strength supports strategic choices without heavy near-term refinancing pressure.
Bears Say
Persistent Unprofitable OperationsConsistent negative net profit, EBIT and EBITDA margins indicate the company has not yet converted revenue into sustainable earnings. Prolonged unprofitability limits reinvestment capacity, impairs ability to self-fund growth, and increases dependence on external capital over months.
Negative Operating And Free Cash FlowsOngoing negative operating and free cash flows create structural cash burn that can erode reserves. Weak cash generation constrains investment in commercial scale-up, forces funding rounds or partnerships, and raises execution risk until operations produce positive cash.
Low Returns On Equity Despite Capital BaseA negative ROE despite a strong equity position signals the business is not translating capital into profit. This persistent inefficiency pressures shareholder value creation and suggests operational or commercial execution must improve to justify the existing capital structure.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.07 and its highest was AU$0.47 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$15.67M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 80 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.10 (-58.33% Downside)
AU$0.10 (-58.33% Downside)
Blogger Sentiment
Bullish
AU:GSS Sentiment 75%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-23.93%
Trailing 12-Months
Asset Growth
-16.90%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
GSS Stock 12 Month Forecast
Average Price Target
AU$0.10
▼(-58.33% Downside)
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―